Literature DB >> 21151188

Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over.

D J Andorsky1, M Cohen, A Naeim, L Pinter-Brown.   

Abstract

The safety and efficacy of auto-SCT for lymphoma in older patients is not well established, particularly in those ≥70 years old. We performed a retrospective analysis comparing 17 auto-SCT recipients ≥70 years old with 39 recipients aged 65-69 years. Hematopoietic cell transplantation comorbidity index (HCT-CI) scores were similar in both groups. Nonrelapse mortality (NRM) was increased in patients aged 70 years and older (hazard ratio (HR) 6.04, P=0.0029), and OS was decreased (HR 1.98, P=0.082). 1-year NRM was 35% in patients aged ≥70 years vs 8% in those aged 65-69 years (P=0.017). The incidence of in-hospital falls was higher in those aged ≥70 years (29 vs 8%, P=0.047). In a secondary exploratory analysis, we found that the occurrence of in-hospital falls was strongly associated with inferior OS (HR 3.36, P=0.0023) and NRM (HR 4.60, P=0.009) among all patients of aged 65 years and older. We conclude that auto-SCT is feasible in older patients but that mortality rates appear increased in those over age of 70 years. In-hospital falls were correlated with higher mortality, and prevention of falls may improve outcomes. Susceptibility to falls may indicate underlying frailty and should be explored prospectively as a means of selecting older patients for auto-SCT.

Entities:  

Mesh:

Year:  2010        PMID: 21151188     DOI: 10.1038/bmt.2010.289

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.

Authors:  E Schorb; C P Fox; K Fritsch; L Isbell; A Neubauer; A Tzalavras; R Witherall; S Choquet; O Kuittinen; D De-Silva; K Cwynarski; C Houillier; K Hoang-Xuan; V Touitou; N Cassoux; J-P Marolleau; J Tamburini; R Houot; V Delwail; G Illerhaus; C Soussain; B Kasenda
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

2.  Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.

Authors:  Tanya M Wildes; Derek L Stirewalt; Bruno Medeiros; Arti Hurria
Journal:  J Natl Compr Canc Netw       Date:  2014-01       Impact factor: 11.908

3.  Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.

Authors:  Lova Sun; Shuli Li; Areej El-Jawahri; Philippe Armand; Bimalangshu R Dey; David C Fisher; Eric D Jacobsen; Caron A Jacobson; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Yi-Bin Chen; Zachariah DeFilipp
Journal:  Oncologist       Date:  2017-12-28

4.  Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care.

Authors:  Rebecca L Olin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.

Authors:  Oscar B Lahoud; Craig S Sauter; Paul A Hamlin; Parastoo Bahrami Dahi
Journal:  Curr Oncol Rep       Date:  2015-09       Impact factor: 5.075

6.  Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.

Authors:  Pashna N Munshi; Yue Chen; Kwang W Ahn; Farrukh T Awan; Amanda Cashen; Geoffrey Shouse; Mazyar Shadman; Paul Shaughnessy; Joanna Zurko; Frederick L Locke; Aaron M Goodman; Jose C Villaboas Bisneto; Craig Sauter; Mohamad A Kharfan-Dabaja; Gabrielle Meyers; Samantha Jaglowski; Alex Herrera; Mehdi Hamadani
Journal:  Transplant Cell Ther       Date:  2022-05-21

7.  Dose-adjusted high-dose chemotherapy with autologous stem cell transplantation for elderly (≥ 70 years old) lymphoma patients.

Authors:  Hiroki Hosoi; Shogo Murata; Toshiki Mushino; Shinobu Tamura; Takashi Sonoki
Journal:  Ann Hematol       Date:  2021-01-06       Impact factor: 3.673

Review 8.  Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.

Authors:  Mengyang Di; Scott F Huntington; Adam J Olszewski
Journal:  Oncologist       Date:  2020-12-09       Impact factor: 5.837

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.